The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...

This review examines how next-generation protein sequencing and analysis technologies are expanding proteomics beyond the ...

The document outlines the non-clinical sequencing and bioinformatics data sponsors need to submit as part of INDs and BLAs for gene-editing therapies.

Service providers must optimize three compression variables simultaneously: video quality, bitrate efficiency/processing power and latency ...